276 related articles for article (PubMed ID: 6489432)
1. Influence of mild thyroid dysfunction on antipyrine clearance and metabolite formation in man.
Teunissen MW; van der Veen EA; Doodeman PJ; Breimer DD
Eur J Clin Pharmacol; 1984; 27(1):99-103. PubMed ID: 6489432
[TBL] [Abstract][Full Text] [Related]
2. Influence of allylisopropylacetamide and phenobarbital treatment on in vivo antipyrine metabolite formation in rats.
Teunissen MW; Van Graft M; Vermeulen NP; Breimer DD
Xenobiotica; 1983 Aug; 13(8):497-502. PubMed ID: 6649682
[TBL] [Abstract][Full Text] [Related]
3. Correlation between antipyrine metabolite formation and theophylline metabolism in humans after simultaneous single-dose administration and at steady state.
Teunissen MW; De Leede LG; Boeijinga JK; Breimer DD
J Pharmacol Exp Ther; 1985 Jun; 233(3):770-5. PubMed ID: 4009489
[TBL] [Abstract][Full Text] [Related]
4. Influence of thyroid status on plasma half-life of antipyrine in man.
Eichelbaum M; Bodem G; Gugler R; Schneider-Deters D; Dengler HJ
N Engl J Med; 1974 May; 290(19):1040-2. PubMed ID: 4821905
[No Abstract] [Full Text] [Related]
5. Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation.
Engel G; Hofmann U; Heidemann H; Cosme J; Eichelbaum M
Clin Pharmacol Ther; 1996 Jun; 59(6):613-23. PubMed ID: 8681486
[TBL] [Abstract][Full Text] [Related]
6. [Effect of disorders of thyroid function on phenazone pharmacokinetics].
Bolanowski M; Orzechowska-Juzwenko K; Gruszka S; Szymczak J
Pol Tyg Lek; 1990 Feb 5-12; 45(6-7):136-9. PubMed ID: 2216953
[TBL] [Abstract][Full Text] [Related]
7. Induction of hexobarbital and antipyrine metabolism by rifampicin treatment in the pig.
van den Broek JM; Teunissen MW; Breimer DD
Drug Metab Dispos; 1981; 9(6):541-4. PubMed ID: 6120813
[TBL] [Abstract][Full Text] [Related]
8. Substrate-selective inhibition by verapamil and diltiazem: differential disposition of antipyrine and theophylline in humans.
Abernethy DR; Egan JM; Dickinson TH; Carrum G
J Pharmacol Exp Ther; 1988 Mar; 244(3):994-9. PubMed ID: 3252045
[TBL] [Abstract][Full Text] [Related]
9. Influence of rifampicin, phenobarbital and cimetidine on mixed function monooxygenase in extensive and poor metabolizers of debrisoquine.
Leclercq V; Desager JP; Horsmans Y; Van Nieuwenhuyze Y; Harvengt C
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):593-8. PubMed ID: 2613393
[TBL] [Abstract][Full Text] [Related]
10. Effect of fusidic acid on the hepatic cytochrome P450 enzyme system.
Reimann G; Barthel B; Rockstroh JK; Spatz D; Brockmeyer NH
Int J Clin Pharmacol Ther; 1999 Nov; 37(11):562-6. PubMed ID: 10584978
[TBL] [Abstract][Full Text] [Related]
11. Antipyrine metabolite formation and excretion in patients with chronic renal failure.
Teunissen MW; Kampf D; Roots I; Vermeulen NP; Breimer DD
Eur J Clin Pharmacol; 1985; 28(5):589-95. PubMed ID: 4043202
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of simultaneously administered antipyrine and theophylline in male BN/BiRij rats before and after induction with 3-methylcholanthrene.
Groen K; Breimer DD; van Bezooijen CF
Drug Metab Dispos; 1992; 20(4):502-6. PubMed ID: 1356725
[TBL] [Abstract][Full Text] [Related]
13. Plasma concentration-response relationship for cimetidine inhibition of drug metabolism in the rat.
Adedoyin A; Aarons L; Houston JB
Drug Metab Dispos; 1987; 15(1):127-32. PubMed ID: 2881749
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of enzyme induction on antipyrine metabolite formation.
Danhof M; Verbeek RM; van Boxtel CJ; Boeijinga JK; Breimer DD
Br J Clin Pharmacol; 1982 Mar; 13(3):379-86. PubMed ID: 7059438
[TBL] [Abstract][Full Text] [Related]
15. The effect of age on antipyrine pharmacokinetics and metabolite formation in rats.
van Bezooijen CF; van Oorschot RM
J Pharmacol Exp Ther; 1989 Nov; 251(2):683-6. PubMed ID: 2810117
[TBL] [Abstract][Full Text] [Related]
16. Changes in drug metabolism in children with thyroid disorders.
Saenger P; Rifkind AB; New MI
J Clin Endocrinol Metab; 1976 Jan; 42(1):155-9. PubMed ID: 1249184
[TBL] [Abstract][Full Text] [Related]
17. The influence of dietary restriction on the metabolism of theophylline and antipyrine in the ageing female BN/BiRij rat.
Groen K; Breimer DD; Brouwer A; Schijff G; Jansen EJ; van Bezooijen CF
J Pharmacol Exp Ther; 1995 Jul; 274(1):143-7. PubMed ID: 7616391
[TBL] [Abstract][Full Text] [Related]
18. Antipyrine clearance and metabolite formation: the influence of liver volume and smoking.
Spoelstra P; Teunissen MW; Janssens AR; Weeda B; van Duijn W; Koch CW; Breimer DD
Eur J Clin Invest; 1986 Aug; 16(4):321-7. PubMed ID: 3093244
[TBL] [Abstract][Full Text] [Related]
19. Antipyrine clearance and metabolite formation in patients with alcoholic cirrhosis.
Teunissen MW; Spoelstra P; Koch CW; Weeda B; van Duyn W; Janssens AR; Breimer DD
Br J Clin Pharmacol; 1984 Nov; 18(5):707-15. PubMed ID: 6508980
[TBL] [Abstract][Full Text] [Related]
20. Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.
Vesell ES; Shapiro JR; Passananti T; Jorgensen H; Shively CA
Clin Pharmacol Ther; 1975 Jan; 17(1):48-56. PubMed ID: 1122669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
